Latest Pharmacyclics Inc (PCYC) Headlines
BioClinica Technology Supports Pharmacyclics in Achieving Early Approval of IMBRUVICA(TM) and Breakthrough Therapy Designations for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)
PR Newswire - Tue Mar 11, 8:00AM CDT
BioClinica®, Inc., a leading provider of specialized outsourced clinical trial services, today announced that its technology was utilized by Pharmacyclics, Inc. (NASDAQ: PCYC) and supported the accelerated approval of IMBRUVICA(TM) (ibrutinib) for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL).
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Pharmacyclics Is Down 7.8% (PCYC)
Comtex SmarTrend(R) - Mon Mar 10, 7:34AM CDT
Two weeks ago on February 20th, 2014 Pharmacyclics (NASDAQ
CYC) reported earnings and analysts, on average, expected earnings of $0.65 on sales of $77.0 million. The company actually reported EPS of $0.95 on sales of $123.6 million, beating EPS estimates by $0.30 and beating revenue estimates by $46.6 million. Since the company's report, shares of Pharmacyclics have fallen from $142.68 to $131.54, representing a loss of 7.8% in the past 18 days.
Pharmacyclics Falls 2.97% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 07, 4:17PM CST
Pharmacyclics (NASDAQCYC) traded in a range yesterday that spanned from a low of $128.50 to a high of $137.50. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $135.00 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
The Growth Driver Johnson & Johnson Investors Need to Watch
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Healthcare giant Johnson & Johnson is one of the most diversified companies in the industry. While many identify the company with its notable consumer brands, which include Band-Aid and Neutrogena products,it always seems to have a steady...
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses
at Investor's Business Daily - Wed Mar 05, 4:38PM CST
Chinese contract research organization WuXi PharmaTech (WX) beat Wall Street's earnings estimates in its Q4 report and 2014 guidance, though revenue was in-line and its Q1 guidance missed expectations. The stock dropped more than 7% in after-hours...
Can Pharmacyclics, Inc.'s Imbruvica Stay Ahead of Gilead Sciences, Inc.'s Idelalisib?
Cory Renauer, The Motley Fool - Motley Fool - Thu Feb 27, 5:30PM CST
Things are looking pretty good lately for Pharmacyclics . Its Imbruvica partnership, with Johnson & Johnson subsidiary Janssen, is racking up approvals. Analysts are predicting some impressive sales, and the market has noticed. The company's...
After Yesterday's Decline of 1.09%, Pharmacyclics Offers Investors Better Value
Comtex SmarTrend(R) - Thu Feb 27, 4:53PM CST
Pharmacyclics (NASDAQCYC) traded in a range yesterday that spanned from a low of $142.68 to a high of $148.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $145.17 on volume of 908,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
1 Drug Critical to Johnson & Johnson's Future Success
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 25, 1:30PM CST
Johnson & Johnson and Pharmacyclics are on a winning streak, and if it's any indication, investors are likely to see more good news coming. The wins are coming courtesy of the cancer drug ibrutinib, a compound that's already won approval...
Pharmacyclics Attains 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:00PM CST
Shares of Pharmacyclics reached a 52-week high of $154.89 during the trading session on Feb 21.
Surging Earnings Estimates Signal Good News for Pharmacyclics (PCYC) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:31AM CST
Pharmacyclics has decent short-term momentum and solid activity on the earnings estimate revision front. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PCYC’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Pharmacyclics could be a solid choice for investors.
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon Feb 24, 2:33AM CST
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
Is Gilead About to Become an Oncology Powerhouse?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 1:37PM CST
There's little doubt that Gilead 's first hepatitis C drug, Sovaldi, is going to be a success. After winning approval in December, Gilead sold $140 million worth of the drug to distributors in anticipation of demand. Gilead hopes it will have...
Pharmacyclics Hits High As Imbruvica Launches Big
at Investor's Business Daily - Fri Feb 21, 11:31AM CST
Biotech firm Pharmacyclics (PCYC) jumped 6.5% to a new high on the stock market today, after its Q4 report revealed a strong launch of its cancer drug Imbruvica. Late Thursday, the company said Imbruvica garnered $13.6 million in net sales in the...
Pharmacyclics Beats on Earnings, Revenues in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 11:10AM CST
Pharmacyclics' fourth quarter earnings beat the Zacks Consensus Estimate by 5 cents.
SmarTrend Watching for Potential Pullback in Shares of Pharmacyclics After 2.75% Gain
Comtex SmarTrend(R) - Thu Feb 20, 4:29PM CST
Pharmacyclics (NASDAQCYC) traded in a range yesterday that spanned from a low of $137.32 to a high of $143.09. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $140.22 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Who Is Responsible For Biotech's Torrid Start to 2014?
at The Street - Thu Feb 20, 3:03PM CST
Biotech investing goes mainstream.
Pharmacyclics Reports Fourth Quarter and Full Year 2013 Results
PR Newswire - Thu Feb 20, 3:01PM CST
Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter and year ended December 31, 2013.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
BioClinica Technology Supports Pharmacyclics in Achieving Early Approval of IMBRUVICA(TM) and Breakthrough Therapy Designations for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL)
PR Newswire - Tue Mar 11, 8:00AM CDT
BioClinica®, Inc., a leading provider of specialized outsourced clinical trial services, today announced that its technology was utilized by Pharmacyclics, Inc. (NASDAQ: PCYC) and supported the accelerated approval of IMBRUVICA(TM) (ibrutinib) for Mantle Cell Lymphoma (MCL) and Chronic Lymphocytic Leukemia (CLL).
Earnings Flashback: Since Reporting Quarterly Results 2 Weeks Ago Pharmacyclics Is Down 7.8% (PCYC)
Comtex SmarTrend(R) - Mon Mar 10, 7:34AM CDT
Two weeks ago on February 20th, 2014 Pharmacyclics (NASDAQ
CYC) reported earnings and analysts, on average, expected earnings of $0.65 on sales of $77.0 million. The company actually reported EPS of $0.95 on sales of $123.6 million, beating EPS estimates by $0.30 and beating revenue estimates by $46.6 million. Since the company's report, shares of Pharmacyclics have fallen from $142.68 to $131.54, representing a loss of 7.8% in the past 18 days. Pharmacyclics Falls 2.97% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Mar 07, 4:17PM CST
Pharmacyclics (NASDAQ
CYC) traded in a range yesterday that spanned from a low of $128.50 to a high of $137.50. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $135.00 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. The Growth Driver Johnson & Johnson Investors Need to Watch
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 07, 1:30PM CST
Healthcare giant Johnson & Johnson is one of the most diversified companies in the industry. While many identify the company with its notable consumer brands, which include Band-Aid and Neutrogena products,it always seems to have a steady...
Jim Cramer: Happy Birthday, You Bogus Bull Market
at The Street - Fri Mar 07, 10:22AM CST
You've rallied 177%, yet many don't seem to believe you exist.
WuXi Pharma Q4 Earnings Top, But Q1 Guidance Misses
at Investor's Business Daily - Wed Mar 05, 4:38PM CST
Chinese contract research organization WuXi PharmaTech (WX) beat Wall Street's earnings estimates in its Q4 report and 2014 guidance, though revenue was in-line and its Q1 guidance missed expectations. The stock dropped more than 7% in after-hours...
Can Pharmacyclics, Inc.'s Imbruvica Stay Ahead of Gilead Sciences, Inc.'s Idelalisib?
Cory Renauer, The Motley Fool - Motley Fool - Thu Feb 27, 5:30PM CST
Things are looking pretty good lately for Pharmacyclics . Its Imbruvica partnership, with Johnson & Johnson subsidiary Janssen, is racking up approvals. Analysts are predicting some impressive sales, and the market has noticed. The company's...
After Yesterday's Decline of 1.09%, Pharmacyclics Offers Investors Better Value
Comtex SmarTrend(R) - Thu Feb 27, 4:53PM CST
Pharmacyclics (NASDAQ
CYC) traded in a range yesterday that spanned from a low of $142.68 to a high of $148.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $145.17 on volume of 908,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. 1 Drug Critical to Johnson & Johnson's Future Success
Todd Campbell, The Motley Fool - Motley Fool - Tue Feb 25, 1:30PM CST
Johnson & Johnson and Pharmacyclics are on a winning streak, and if it's any indication, investors are likely to see more good news coming. The wins are coming courtesy of the cancer drug ibrutinib, a compound that's already won approval...
Pharmacyclics Attains 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 4:00PM CST
Shares of Pharmacyclics reached a 52-week high of $154.89 during the trading session on Feb 21.
Surging Earnings Estimates Signal Good News for Pharmacyclics (PCYC) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 7:31AM CST
Pharmacyclics has decent short-term momentum and solid activity on the earnings estimate revision front. These positive earnings estimate revisions suggest that analysts are becoming more optimistic on PCYC’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Pharmacyclics could be a solid choice for investors.
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon Feb 24, 2:33AM CST
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
Is Gilead About to Become an Oncology Powerhouse?
Todd Campbell, The Motley Fool - Motley Fool - Fri Feb 21, 1:37PM CST
There's little doubt that Gilead 's first hepatitis C drug, Sovaldi, is going to be a success. After winning approval in December, Gilead sold $140 million worth of the drug to distributors in anticipation of demand. Gilead hopes it will have...
Pharmacyclics Hits High As Imbruvica Launches Big
at Investor's Business Daily - Fri Feb 21, 11:31AM CST
Biotech firm Pharmacyclics (PCYC) jumped 6.5% to a new high on the stock market today, after its Q4 report revealed a strong launch of its cancer drug Imbruvica. Late Thursday, the company said Imbruvica garnered $13.6 million in net sales in the...
Pharmacyclics Beats on Earnings, Revenues in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 11:10AM CST
Pharmacyclics' fourth quarter earnings beat the Zacks Consensus Estimate by 5 cents.
SmarTrend Watching for Potential Pullback in Shares of Pharmacyclics After 2.75% Gain
Comtex SmarTrend(R) - Thu Feb 20, 4:29PM CST
Pharmacyclics (NASDAQ
CYC) traded in a range yesterday that spanned from a low of $137.32 to a high of $143.09. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $140.22 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. Who Is Responsible For Biotech's Torrid Start to 2014?
at The Street - Thu Feb 20, 3:03PM CST
Biotech investing goes mainstream.
Pharmacyclics Reports Fourth Quarter and Full Year 2013 Results
PR Newswire - Thu Feb 20, 3:01PM CST
Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) today reported financial results and recent developments for the quarter and year ended December 31, 2013.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
